Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

10 First Approvals To Look Out For In 2018

Executive Summary

Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.

Advertisement

Related Content

J&J To Get EU Fast-Track Decision On Apalutamide
Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study
J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?
Portola's Supplementary Approval Paves Way For Belated Bevyxxa Launch
Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine
Is Triple Phase III Triumph for AbbVie's Risankizumab In Psoriasis Good Enough?
Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way
Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win
Theratechnologies' Novel AIDS Drug Filed In US
Sun’s Tildrakizumab Shines In Pivotal Psoriasis Trials

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100321

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel